KR102502158B1 - Composition for promoting hair growth and/or inhibiting hair loss - Google Patents

Abstract

The present application relates to a composition for hair growth and/or hair loss inhibition comprising a crude drug extract and/or an active compound as an active ingredient.

Description

Composition for promoting hair growth and/or inhibiting hair loss

The present application relates to a composition for hair growth and/or hair loss inhibition comprising a crude drug extract and/or an active compound as an active ingredient.

Human hair originates from hair follicles present in the scalp. Originally, hair follicles are formed in the fetal period and are no longer generated after birth, so the number of hair follicles is maintained constant through adolescence to adulthood and gradually decreases from old age. Human hair repeats growth and extinction through a unique cycle of anagen stage, catagen stage, and telogen stage. This cycle of hair is repeated over 3 to 6 years, and it is known that it is affected by various factors such as age, season, disease, stress, etc. in addition to genetic factors. In general, alopecia refers to an abnormally large number of hairs falling out due to an increase in hair in the catagen or telogen phase, while the amount of hair in the growth phase decreases during the aforementioned hair cycle.

In general, hair loss is caused by genetics, aging, disease, drug intake, radiation treatment, etc., but from a biochemical or physiological point of view, the cause of hair loss is oversecretion of male hormones, oversecretion of sebum, scalp blood circulation disorder, nutrient deficiency, and nutritional imbalance. , stress, etc. However, the exact cause and mechanism of action of hair loss have not yet been identified, and clear methods or drugs for treating alopecia are also very lacking.

delete

KR 10-1440061 B1. CN 105853410 A.

Biochemical and Biphysical Research Communications, 472, 250-254, 2016.

An example of the present application is one or more selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient. It provides a composition for hair growth comprising.

Another example is broccoli ( Brassica oleracea var. italica) extract, avocado ( Persea americana ) extract, or provides a composition for hair growth containing a mixture thereof as an active ingredient.

The composition for hair growth may be a pharmaceutical composition, a cosmetic composition, and/or a food composition (eg, health functional food).

Another embodiment provides a pharmaceutical composition for preventing or treating hair loss comprising at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient.

Another example provides a pharmaceutical composition for preventing, improving, or treating hair loss, comprising a broccoli extract, an avocado extract, or a mixture thereof as an active ingredient.

Another example provides a cosmetic composition for preventing or improving hair loss, comprising at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient.

Another example provides a cosmetic composition for preventing or improving hair loss, comprising a broccoli extract, an avocado extract, or a mixture thereof as an active ingredient.

Another example provides a food composition for preventing or improving hair loss, comprising at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient. The food composition may be a health functional food.

Another example provides a food composition for preventing or improving hair loss, comprising a broccoli extract, an avocado extract, or a mixture thereof as an active ingredient. The food composition may be a health functional food.

Another example is to administer an effective amount of at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof to a subject in need of prevention, improvement, or treatment of hair growth and/or hair loss. It provides a method for preventing, improving, or treating hair growth and/or hair loss comprising the step.

Another example is prevention, improvement of hair growth and/or hair loss, comprising administering an effective amount of a broccoli extract, an avocado extract, or a mixture thereof to a subject in need of prevention, improvement, or treatment of hair growth and/or hair loss; or a method of treatment.

Another example is prevention, improvement, or treatment of hair growth and/or hair loss, or prevention of hair growth and/or hair loss, at least one member selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof. , improvement, or use for use in the preparation of therapeutic compositions.

Another example is the use of broccoli extract, avocado extract, or mixtures thereof for use in the preparation of a composition for preventing, improving, or treating hair growth and/or hair loss, or for preventing, improving, or treating hair growth and/or hair loss. provides

In the present specification, herbal extracts and useful compounds having an effect of inhibiting hair growth and/or hair loss are identified, and uses thereof for inhibiting hair growth and/or hair loss are provided.

More specifically, one example is one or more selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof, or salts thereof. It provides a composition for hair growth comprising a.

Another example is broccoli ( Brassica oleracea var. italica) extract, avocado ( Persea americana ) extract, or provides a composition for hair growth containing a mixture thereof as an active ingredient.

The composition for hair growth may be a pharmaceutical composition, a cosmetic composition, and/or a food composition (eg, health functional food).

Another embodiment provides a pharmaceutical composition for preventing, improving, or treating hair loss, comprising at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient. .

Another example provides a pharmaceutical composition for preventing, improving, or treating hair loss, comprising a broccoli extract, an avocado extract, or a mixture thereof as an active ingredient.

Another example provides a cosmetic composition for preventing or improving hair loss, comprising at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient.

Another example provides a cosmetic composition for preventing or improving hair loss, comprising a broccoli extract, an avocado extract, or a mixture thereof as an active ingredient.

Another example provides a food composition for preventing or improving hair loss, comprising at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof as an active ingredient. The food composition may be a health functional food.

Another example provides a food composition for preventing or improving hair loss, comprising a broccoli extract, an avocado extract, or a mixture thereof as an active ingredient. The food composition may be a health functional food.

Another example is to administer an effective amount of at least one selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof to a subject in need of prevention, improvement, or treatment of hair growth and/or hair loss. It provides a method for preventing, improving, or treating hair growth and/or hair loss comprising the step.

Another example is prevention, improvement of hair growth and/or hair loss, comprising administering an effective amount of a broccoli extract, an avocado extract, or a mixture thereof to a subject in need of prevention, improvement, or treatment of hair growth and/or hair loss; or a method of treatment.

Another example is prevention, improvement, or treatment of hair growth and/or hair loss, or prevention of hair growth and/or hair loss, at least one member selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof. , improvement, or use for use in the preparation of therapeutic compositions.

Another example is the use of broccoli extract, avocado extract, or mixtures thereof for use in the preparation of a composition for preventing, improving, or treating hair growth and/or hair loss, or for preventing, improving, or treating hair growth and/or hair loss. provides

Any numerical value or numerical range related to the compositions and methods provided herein contributes to the purpose of the compositions and methods, such as promoting hair growth and/or inhibiting hair loss (prevention, improvement, and/or treatment of hair loss), or has a more beneficial effect. It may be selected to indicate.

Hereinafter, the present invention will be described in more detail.

active compound

The sulforaphane (SFN) is a compound having a chemical formula of C ₆ H ₁₁ NOS ₂ (CAS No. 4478-93-7) and may have a structure represented by Chemical Formula 1 below.

[Formula 1]

The indole-3-carbinol (I3C) is a compound having a chemical formula of C ₉ H ₉ NO (CAS No. 700-06-1) and may have a structure represented by Chemical Formula 2 below.

[Formula 2]

The β-sitosterol (β-sitosterol) is a compound having a chemical formula of C ₂₉ H ₅₀ O (CAS No. 83-46-5) and may have a structure represented by Chemical Formula 3 below.

[Formula 3]

The compounds of Formulas 1 to 3 or salts thereof may be obtained by extraction and/or separation from natural products and/or strains, or may be prepared by conventional organic synthesis methods, but are not limited thereto.

In the present application, "salt of a compound" may mean a physiologically acceptable salt among salts in which cations and anions are bonded by electrostatic attraction, for example, pharmaceutically acceptable salts, acceptable salts for cosmetics. salt, and/or a food-acceptable salt. For example, the salt may be at least one selected from the group consisting of a metal salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, and a salt with a basic or acidic amino acid. In one example, the metal salt may be at least one selected from the group consisting of alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (calcium salts, magnesium salts, barium salts, etc.), aluminum salts, and the like; Salts with organic bases are triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine, and the like. It may be one or more selected from the group consisting of salts of; The salt with an inorganic acid may be at least one selected from the group consisting of salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like; The salt with an organic acid is at least one selected from the group consisting of salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. can; Salts with basic amino acids may be at least one selected from the group consisting of salts with arginine, lysine, ornithine, and the like; The salt with an acidic amino acid may be at least one selected from the group consisting of salts with aspartic acid and glutamic acid.

In one example, the active ingredient may be sulforaphane.

In another example, the active ingredient may be indole-3-carbinol.

In another example, the active ingredient may be beta-sitosterol.

In another example, the active ingredient may be a combination of sulforaphane and indole-3-carbinol. In this case, the ratio between sulforaphane and indole-3carbinol contained in a composition provided herein or administered in a method, by weight, is 10:0.1 to 10, 10:0.1 to 7.5, 10:0.1 to 5, 10 : 0.1 to 2.5, 10: 0.1 to 2, 10: 0.1 to 1.5, 10: 0.1 to 1.25, 10: 0.25 to 10, 10: 0.25 to 7.5, 10: 0.25 to 5, 10: 0.25 to 2.5, 10: 0.25 to 2, 10: 0.25 to 1.5, 10: 0.25 to 1.25, 10: 0.5 to 10, 10: 0.5 to 7.5, 10: 0.5 to 5, 10: 0.5 to 2.5, 10: 0.5 to 2, 10: 0.5 to 1.5 , 10: 0.5 to 1.25, 10: 0.75 to 10, 10: 0.75 to 7.5, 10: 0.75 to 5, 10: 0.75 to 2.5, 10: 0.75 to 2, 10: 0.75 to 1.5, 10: 0.75 to 1.25, 10 : 1 to 10, 10: 1 to 7.5, 10: 1 to 5, 10: 1 to 2.5, 10: 1 to 2, 10: 1 to 1.5, 10: 1 to 1.25, 10: 1.25 to 10, 10: 1.25 to 7.5, 10: 1.25 to 5, 10: 1.25 to 2.5, 10: 1.25 to 2, 10: 1.25 to 1.5, 10: 2.5 to 10, 10: 2.5 to 7.5, 10: 2.5 to 5, about 10: 1.25, Or it may be about 10: 2.5 (or more, weight of sulforaphane: weight of indole-3-carbinol).

In another example, the active ingredient may be a combination of sulforaphane and beta-sitosterol. In this case, the ratio between sulforaphane and beta-sitosterol contained in a composition provided herein or administered in a method, by weight, is 10:0.1 to 10, 10:0.1 to 7.5, 10:0.1 to 5, 10:0.1 to 2.5, 10: 0.1 to 2, 10: 0.1 to 1.5, 10: 0.1 to 1.25, 10: 0.25 to 10, 10: 0.25 to 7.5, 10: 0.25 to 5, 10: 0.25 to 2.5, 10: 0.25 to 2 , 10: 0.25 to 1.5, 10: 0.25 to 1.25, 10: 0.5 to 10, 10: 0.5 to 7.5, 10: 0.5 to 5, 10: 0.5 to 2.5, 10: 0.5 to 2, 10: 0.5 to 1.5, 10 : 0.5 to 1.25, 10: 0.75 to 10, 10: 0.75 to 7.5, 10: 0.75 to 5, 10: 0.75 to 2.5, 10: 0.75 to 2, 10: 0.75 to 1.5, 10: 0.75 to 1.25, 10: 1 to 10, 10: 1 to 7.5, 10: 1 to 5, 10: 1 to 2.5, 10: 1 to 2, 10: 1 to 1.5, 10: 1 to 1.25, 10: 1.25 to 10, 10: 1.25 to 7.5 , 10: 1.25 to 5, 10: 1.25 to 2.5, 10: 1.25 to 2, 10: 1.25 to 1.5, 10: 2.5 to 10, 10: 2.5 to 7.5, 10: 2.5 to 5, about 10: 1.25, or about 10: 2.5 (ideally, sulforaphane weight: beta-sitosterol weight).

In another example, the active ingredient may be a combination of indole-3-carbinol and beta-sitosterol. In this case, the ratio between indole-3-carbinol and beta-sitosterol contained in a composition provided herein or administered in a method, by weight, is from 1:0.1 to 10, 1:0.1 to 7.5, 1:0.1 to 1:0.1. 5, 1: 0.1 to 2.5, 1: 0.1 to 1, 1: 0.25 to 10, 1: 0.25 to 7.5, 1: 0.25 to 5, 1: 0.25 to 2.5, 1: 0.25 to 1, 1: 0.5 to 10, 1: 0.5 to 7.5, 1: 0.5 to 5, 1: 0.5 to 2.5, 1: 0.5 to 1, 1: 0.75 to 10, 1: 0.75 to 7.5, 1: 0.75 to 5, 1: 0.75 to 2.5, 1: 0.75 to 1, 1:1 to 10, 1:1 to 7.5, 1:1 to 5, 1:1 to 2.5, or about 1:1 (ideal, indole-3-carbinol weight: beta-sitosterol weight) days can

In another example, the active ingredient may be a combination of sulforaphane, indole-3-carbinol, and beta-sitosterol. In this case, the ratio between sulforaphane, indole-3-carbinol, and beta-sitosterol contained in a composition provided herein or administered in a method, by weight, is from 10:0.1 to 10:0.1 to 10, 10:0.1 to 7.5: 0.1 to 7.5, 10: 0.1 to 5: 0.1 to 5, 10: 0.1 to 2.5: 0.1 to 2.5, 10: 0.1 to 2: 0.1 to 2, 10: 0.1 to 1.5: 0.1 to 1.5, 10: 0.1 to 1.25: 0.1 to 1.25, 10: 0.25 to 10: 0.25 to 10, 10: 0.25 to 7.5: 0.25 to 7.5, 10: 0.25 to 5: 0.25 to 5, 10: 0.25 to 2.5: 0.25 to 2.5, 10: 0.25 to 2: 0.25 to 2, 10: 0.25 to 1.5: 0.25 to 1.5, 10: 0.25 to 1.25: 0.25 to 1.25, 10: 0.5 to 10: 0.5 to 10, 10: 0.5 to 7.5: 0.5 to 7.5, 10: 0.5 to 5: 0.5 to 5, 10: 0.5 to 2.5: 0.5 to 2.5, 10: 0.5 to 2: 0.5 to 2, 10: 0.5 to 1.5: 0.5 to 1.5, 10: 0.5 to 1.25: 0.5 to 1.25, 10: 0.75 to 10: 0.75 to 10, 10: 0.75 to 7.5: 0.75 to 7.5, 10: 0.75 to 5: 0.75 to 5, 10: 0.75 to 2.5: 0.75 to 2.5, 10: 0.75 to 2: 0.75 to 2, 10: 0.75 to 1.5: 0.75 to 1.5, 10: 0.75 to 1.25: 0.75 to 1.25, 10: 1 to 10: 1 to 10, 10: 1 to 7.5: 1 to 7.5, 10: 1 to 5: 1 to 5, 10: 1 to 2.5: 1 to 2.5, 10: 1 to 2: 1 to 2, 10: 1 to 1.5: 1 to 1.5, 10: 1 to 1.25: 1 to 1.25, 10: 1.25 to 10: 1.25 to 10, 10: 1.25 to 7.5: 1.25 to 7.5, 10: 1.25 to 5: 1.25 to 5, 10: 1.25 to 2.5: 1.25 to 2.5, 10: 1.25 to 2, 10: 1.25 to 1.5: 1.25 to 1.5, or 10: 1.25: 1.25 (or more, sulforaphane weight: indole-3-carbinol weight: beta-sitosterol weight).

In one example, sulforaphane, indole-3-carbinol, beta-sitosterol, and/or salts thereof described as active ingredients in the composition and/or method provided herein are contained in broccoli extract, avocado extract, or a mixture thereof. It may be in a form or in a form isolated (or purified) therefrom.

extract

Broccoli ( Brassica oleracea var. italica) is an annual dicotyledonous plant belonging to the mustard family, and is used in various ways for food. The broccoli extract used herein may be obtained by using one or more parts selected from the group consisting of broccoli seeds, sprouts, flowers, leaves, roots, and outposts. The sprout may refer to the first stem and/or leaf generated from a seed. Broccoli used for extraction in the present specification may be in the form of a raw material, a dried material, or a crushed product of the crude drug or dried material, but is not limited thereto.

Avocado ( Persea americana ) is a dicotyledonous plant belonging to the Lauraceae family, and is a fruit native to Mexico and Central America. The avocado extract used herein may be obtained by using one or more parts selected from the group consisting of seeds, fruits (flesh and/or peel), sprouts, flowers, stems, roots, and outposts of avocados. The sprout may refer to the first stem and/or leaf generated from a seed. The avocado used for extraction in the present specification may be in the form of a raw material, a dried material, or a crushed product of the crude drug or dried material, but is not limited thereto.

The broccoli extract may be obtained by extracting broccoli with one or more extraction solvents selected from the group consisting of water and a straight-chain or branched alcohol having 1 to 4 carbon atoms. In one example, the broccoli extract is broccoli in water, or 5 to 100% (v / v), 5 to 98% (v / v), 5 to 95% (v / v), 5 to 92% (v / v) v), 5 to 90% (v/v), 5 to 85% (v/v), 5 to 80% (v/v), 5 to 75% (v/v), 5 to 70% (v/v) v), 5 to 65% (v/v), 5 to 60% (v/v), 5 to 55% (v/v), 5 to 50% (v/v), 5 to 45% (v/v) v), 5 to 40% (v/v), 5 to 35% (v/v), 5 to 30% (v/v), 5 to 25% (v/v), 5 to 20% (v/v) v), 5 to 15% (v/v), 5 to 10% (v/v), 10 to 100% (v/v), 10 to 98% (v/v), 10 to 95% (v/v) v), 10 to 92% (v/v), 10 to 90% (v/v), 10 to 85% (v/v), 10 to 80% (v/v), 10 to 75% (v/v) v), 10 to 70% (v/v), 10 to 65% (v/v), 10 to 60% (v/v), 10 to 55% (v/v), 10 to 50% (v/v) v), 10 to 45% (v/v), 10 to 40% (v/v), 10 to 35% (v/v), 10 to 30% (v/v), 10 to 25% (v/v) v), 10 to 20% (v/v), 10 to 15% (v/v), 15 to 100% (v/v), 15 to 98% (v/v), 15 to 95% (v/v) v), 15 to 92% (v/v), 15 to 90% (v/v), 15 to 85% (v/v), 15 to 80% (v/v), 15 to 75% (v/v) v), 15 to 70% (v/v), 15 to 65% (v/v), 15 to 60% (v/v), 15 to 55% (v/v), 15 to 50% (v/v) v), 15 to 45% (v/v), 15 to 40% (v/v), 15 to 35% (v/v), 15 to 30% (v/v), 15 to 25% (v/v) v), 15 to 20% (v/v), 20 to 100% (v/v), 20 to 98% (v/v), 20 to 95% (v/v), 20 to 92% (v/v), 20 to 90% (v/v), 20 to 85% (v/v), 20 to 80% (v/v), 20 to 75% (v/v), 20 to 70% (v/v), 20 to 65% (v/v), 20 to 60% (v/v), 20 to 55% (v/v), 20 to 50% (v/v), 20 to 45% (v/v), 20 to 40% (v/v), 20 to 35% (v/v), 20 to 30% (v/v), 20 to 25% (v/v), 25 to 100% (v/v), 25 to 98% (v/v), 25 to 95% (v/v), 25 to 92% (v/v), 25 to 90% (v/v), 25 to 85% (v/v), 25 to 80% (v/v), 25 to 75% (v/v), 25 to 70% (v/v), 25 to 65% (v/v), 25 to 60% (v/v), 25 to 55% (v/v), 25 to 50% (v/v), 25 to 45% (v/v), 25 to 40% (v/v), 25 to 35% (v/v), 25 to 30% (v/v), 30 to 100% (v/v), 30 to 98% (v/v), 30 to 95% (v/v), 30 to 28% (v/v), 30 to 90% (v/v), 30 to 85% (v/v), 30 to 80% (v/v), 30 to 75% (v/v), 30 to 70% (v/v), 30 to 65% (v/v), 30 to 60% (v/v), 30 to 55% (v/v), 30 to 50% (v/v), 30 to 45% (v/v), 30 to 40% (v/v), 30 to 35% (v/v), 35 to 100% (v/v), 35 to 98% (v/v), 35 to 95% (v/v), 35 to 92% (v/v), 35 to 90% (v/v), 35 to 85% (v/v), 35 to 80% (v/v), 35 to 75% (v/v), 35 to 70% (v/v), 35 to 65% (v/v), 35 to 60% (v/v), 35 to 55% (v/v), 35 to 50% (v/v) , 35 to 45% (v / v), 35 to 40% (v / v), 40 to 100% (v / v), 40 to 98% (v / v), 40 to 95% (v / v) , 40 to 92% (v / v), 40 to 90% (v / v), 40 to 85% (v / v), 40 to 80% (v / v), 40 to 75% (v / v) , 40 to 70% (v / v), 40 to 65% (v / v), 40 to 60% (v / v), 40 to 55% (v / v), 40 to 50% (v / v) , 40 to 45% (v / v), 45 to 100% (v / v), 45 to 98% (v / v), 45 to 95% (v / v), 45 to 92% (v / v) , 45 to 90% (v / v), 45 to 85% (v / v), 45 to 80% (v / v), 45 to 75% (v / v), 45 to 70% (v / v) , 45 to 65% (v / v), 45 to 60% (v / v), 45 to 55% (v / v), 45 to 50% (v / v), 50 to 100% (v / v) , 50 to 98% (v / v), 50 to 95% (v / v), 50 to 92% (v / v), 50 to 90% (v / v), 50 to 85% (v / v) , 50 to 80% (v / v), 50 to 75% (v / v), 50 to 70% (v / v), 50 to 65% (v / v), 50 to 60% (v / v) , 50 to 55% (v / v), 55 to 100% (v / v), 55 to 98% (v / v), 55 to 95% (v / v), 55 to 92% (v / v) , 55 to 90% (v / v), 55 to 85% (v / v), 55 to 80% (v / v), 55 to 75% (v / v), 55 to 70% (v / v) , 55 to 65% (v / v), 55 to 60% (v / v), 60 to 100% (v / v), 60 to 98% (v / v), 60 to 95% (v / v) , 60 to 92% (v / v), 60 to 90% (v / v), 60 to 85% (v / v), 60 to 80% (v / v), 60 to 75% (v / v) , 60 to 70% (v / v), 60 to 65% (v / v), 6 5 to 100% (v/v), 65 to 98% (v/v), 65 to 95% (v/v), 65 to 92% (v/v), 65 to 90% (v/v), 65 to 85% (v/v), 65 to 80% (v/v), 65 to 75% (v/v), 65 to 70% (v/v), 70 to 100% (v/v), 70 to 98% (v/v), 70 to 95% (v/v), 70 to 92% (v/v), 70 to 90% (v/v), 70 to 85% (v/v), 70 to 80% (v/v), 70 to 75% (v/v), 75 to 100% (v/v), 75 to 98% (v/v), 75 to 95% (v/v), 75 to 92% (v/v), 75 to 90% (v/v), 75 to 85% (v/v), 75 to 80% (v/v), 80 to 100% (v/v), 80 to 98% (v/v), 80 to 95% (v/v), 80 to 92% (v/v), 80 to 90% (v/v), 80 to 85% (v/v), 85 to 100% (v/v), 85 to 98% (v/v), 85 to 95% (v/v), 85 to 92% (v/v), 85 to 90% (v/v), 90 to 100% (v/v), 90 to 98% (v/v), 90 to 95% (v/v), 90 to 92% (v/v), 95 to 100% (v/v), Or it may be an extract extracted with a 95 to 98% (v/v) aqueous alcohol solution (a combination of water and alcohol (mixture)), such as an ethanol aqueous solution (a combination of water and ethanol (mixture)).

The broccoli extract is 30 to 100 ℃, 30 to 90 ℃, 30 to 80 ℃, 30 to 75 ℃, 30 to 70 ℃, 30 to 65 ℃, 30 to 60 ℃, 30 to 50 ℃, 30 to 40 ℃, 40 to 100°C, 40 to 90°C, 40 to 80°C, 40 to 75°C, 40 to 70°C, 40 to 65°C, 40 to 60°C, 40 to 50°C, 50 to 100°C, 50 to 90°C, 50 to 80°C, 50 to 75°C, 50 to 70°C, 50 to 65°C, 50 to 60°C, 60 to 100°C, 60 to 90°C, 60 to 80°C, 60 to 75°C, 60 to 70°C, 60°C to 65°C, 65 to 100°C, 65 to 90°C, 65 to 80°C, 65 to 75°C, 65 to 70°C, 70 to 100°C, 70 to 90°C, 70 to 80°C, 70 to 75°C, 75°C to 100 °C, 75 to 90 °C, 75 to 80 °C, 80 to 100 °C, 80 to 90 °C or 90 to 100 °C.

The avocado extract may be an extract obtained by extracting avocado with a water-insoluble organic solvent, such as petroleum ether (CAS No. 101316-46-5).

The extraction time of the broccoli and / or avocado extraction step is sufficient as long as the extraction can be sufficiently performed, and is 1 hour or more, 2 hours or more, 3 hours or more, or 4 hours or more, such as 1 to 24 hours, 2 to 24 hours hour, 3 to 24 hours, 4 to 24 hours, 1 to 12 hours, 2 to 12 hours, 3 to 12 hours, 4 to 12 hours, 1 to 6 hours, 2 to 6 hours, 3 to 6 hours, or 4 to 6 hours It may be set to about 6 hours, but is not limited thereto.

The extraction process for obtaining the broccoli extract and/or avocado extract may be performed by any conventionally used extraction method, for example, by one or more methods selected from the group consisting of hot water extraction, ultrasonic extraction, reflux extraction, and the like. It may be performed, but is not limited thereto. After the above extraction process, it may optionally further include drying and/or concentrating the extract in a conventional manner.

The extraction may be performed once or twice or more (eg, 2 times, 3 times, 4 times, or 5 times).

The mixing ratio of the broccoli extract and the avocado extract in the mixture of the extracts, based on solid content weight, was 1:0.1 to 10, 1:0.1 to 5, 1:0.1 to 4, 1:0.1 to 3, 1:0.1 to 2.5, 1 :0.1 to 2, 1:0.1 to 1.5, 1:0.1 to 1, 1:0.1 to 0.67, 1:0.1 to 0.5, 1:0.1 to 0.4, 1:0.1 to 0.33, 1:0.1 to 0.25, 1:0.1 to 0.2, 1:0.2 to 10, 1:0.2 to 5, 1:0.2 to 4, 1:0.2 to 3, 1:0.2 to 2.5, 1:0.2 to 2, 1:0.2 to 1.5, 1:0.2 to 1 , 1:0.2 to 0.67, 1:0.2 to 0.5, 1:0.2 to 0.4, 1:0.2 to 0.33, 1:0.2 to 0.25, 1:0.25 to 10, 1:0.25 to 5, 1:0.25 to 4, 1 :0.25 to 3, 1:0.25 to 2.5, 1:0.25 to 2, 1:0.25 to 1.5, 1:0.25 to 1, 1:0.25 to 0.67, 1:0.25 to 0.5, 1:0.25 to 0.4, 1:0.25 to 0.33, 1:0.33 to 10, 1:0.33 to 5, 1:0.33 to 4, 1:0.33 to 3, 1:0.33 to 2.5, 1:0.33 to 2, 1:0.33 to 1.5, 1:0.33 to 1 , 1:0.33 to 0.67, 1:0.33 to 0.5, 1:0.33 to 0.4, 1:0.4 to 10, 1:0.4 to 5, 1:0.4 to 4, 1:0.4 to 3, 1:0.4 to 2.5, 1 :0.4 to 2, 1:0.4 to 1.5, 1:0.4 to 1, 1:0.4 to 0.67, 1:0.4 to 0.5, 1:0.5 to 10, 1:0.5 to 5, 1:0.5 to 4, 1:0.5 to 3, 1:0.5 to 2.5, 1:0.5 to 2, 1:0.5 to 1.5, 1:0.5 to 1, or 1:0.5 to 0.67 (or more, broccoli solid content weight of the extract: solid content weight of the avocado extract). The weight of the solid content refers to the weight of the solid remaining after removing the solvent component of the extract. This is a term used to indicate that the mixing ratio refers to the ratio between the weights of active ingredients from which the extraction solvent is removed so as not to be affected by the properties and / or concentration of the extract.

The broccoli extract, avocado extract, or mixtures thereof described herein may be in the form of an extract (undiluted solution), a concentrate of an extract, or a dried product of the extract or concentrate.

The extract may include one or more selected from the group consisting of sulforaphane, indole-3-carbinol, beta-sitosterol, and salts thereof.

Usage

The active ingredient (compound and/or extract) provided herein, the composition containing the same, and the method of using the same have hair growth (or hair growth promotion) and/or hair loss inhibition (prevention, improvement, and/or treatment) effects. can have

In the present specification, 'hair growth' refers to all actions that induce and/or promote hair generation and/or growth, and 'hair loss' refers to all conditions in which hair is reduced. The hair cycle includes an anagen phase in which hair grows, a catagen phase in which hair growth stops and hair follicles shrink, a telogen phase in which new hair is generated and old hair is shed, and a telogen phase in which new hair is generated and old hair is lost. As the final stage of hair growth, it can be divided into a new anagen stage in which new hair is generated. Hair may have a periodicity by repeating the development phase, the growth phase, the catagen phase, and the telogen phase. If there are hair loss symptoms, the telogen phase may be prolonged.

In the present application, 'treatment' is used in the meaning of any one or more selected from or encompassing alleviation, improvement, alleviation of symptoms (hair loss), reduction of the range of symptoms, delay of symptom progression, and the like. 'Prevention' is used in the sense of including all mechanisms and/or effects that act on subjects who do not have symptoms (hair loss) to prevent the symptoms from appearing or to delay the onset of the symptoms. "Improvement" may mean at least reducing a parameter related to a condition in which a symptom is treated by administration of a composition according to an embodiment, for example, the severity of a symptom.

The composition provided herein (pharmaceutical composition, cosmetic composition and/or food composition), and/or active ingredient (active compound and/or extract) is applied to humans, dogs, cats, horses, cows, pigs, and goats. , mammals, including rabbits, mice, rats, and the like, such as humans.

In the pharmaceutical composition or method related thereto, the composition and/or active ingredient may be administered or applied in any manner commonly used, such as oral administration or skin (eg, scalp). It may be parenteral administration, such as application, transdermal administration (through the scalp), and the like. The composition may be administered in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., or parenteral formulations such as suspensions, emulsions, aerosols, ointments, patches, gels, etc., according to conventional methods. It may be formulated into a dosage form or the like and used.

The pharmaceutical composition provided herein may further contain adjuvants such as pharmaceutically and/or physiologically acceptable carriers, excipients, and/or diluents in addition to the above active ingredients. Examples of the carrier, excipient, or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, and at least one selected from the group consisting of microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In the case of formulation, one or more diluents or excipients selected from the group consisting of commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like may be used. Solid preparations for oral administration include at least one selected from the group consisting of tablets, pills, powders, granules, capsules, syrups, powders, suspensions, etc. These solid preparations include at least one excipient, For example, it may be prepared by mixing at least one selected from the group consisting of starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include at least one selected from the group consisting of suspensions, solutions for internal use, emulsions, syrups, etc., and various excipients such as wetting agents and sweeteners in addition to water and liquid paraffin, which are commonly used simple diluents At least one selected from the group consisting of, aromatics, preservatives, and the like may be included. Preparations for parenteral administration include at least one selected from the group consisting of sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and transdermal preparations. At least one selected from the group consisting of propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used as the non-aqueous solvent or suspension.

The content of the active ingredient (active compound (sulforaphane, indole-3-carbinol, β-sitosterol, or a combination thereof) and/or extract (solid content)) contained in the pharmaceutical composition depends on the form of the formulation, the desired effect, etc. For example, 0.0001 to 99% by weight, 0.0001 to 90% by weight, 0.0001 to 80% by weight, 0.0001 to 70% by weight, 0.0001 to 60% by weight, 0.0001 to 50% by weight of the total weight of the pharmaceutical composition. %, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.01 to 99% by weight, 0.01 to 90% by weight, 0.01 to 80% by weight, 0.01 to 70% by weight, 0.01 to 60% by weight, 0.01 to 50% by weight, 0.01 to 40% by weight, 0.01 to 30% by weight, 0.01 to 20% by weight, 0.01 to 10% by weight, 1 to 99% by weight, 1 to 90% by weight, 1 to 80 wt%, 1 to 70 wt%, 1 to 60 wt%, 1 to 50 wt%, 1 to 40 wt%, 1 to 30 wt%, 1 to 20 wt%, 1 to 10 wt%, 5 to 99 wt% %, 5 to 90% by weight, 5 to 80% by weight, 5 to 70% by weight, 5 to 60% by weight, 5 to 50% by weight, 5 to 40% by weight, 5 to 30% by weight, 5 to 20% by weight, 5 to 10% by weight, 10 to 99% by weight, 10 to 90% by weight, 10 to 80% by weight, 10 to 70% by weight, 10 to 60% by weight, 10 to 50% by weight, 10 to 40% by weight, 10 to 30 wt%, 10 to 20 wt%, 20 to 99 wt%, 20 to 90 wt%, 20 to 80 wt%, 20 to 70 wt%, 20 to 60 wt%, 20 to 50 wt%, 20 to 40 wt% %, 20 to 30% by weight, 30 to 99% by weight, within 30 90 wt%, 30 to 80 wt%, 30 to 70 wt%, 30 to 60 wt%, 30 to 50 wt%, 30 to 40 wt%, 40 to 99 wt%, 40 to 90 wt%, 40 to 80 wt% 40 to 70% by weight, 40 to 60% by weight, 40 to 50% by weight, 50 to 99% by weight, 50 to 90% by weight, 50 to 80% by weight, 50 to 70% by weight, 50 to 60% by weight , 60 to 99%, 60 to 90%, 60 to 80%, or 60 to 70%.

In addition to the above active ingredients, the cosmetic composition provided in the present specification may further include ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and conventional adjuvants such as fragrances, And it may further include one or more selected from the group consisting of a carrier and the like. As the carrier, purified water, monohydric alcohols (ethanol or propyl alcohol), polyhydric alcohols (glycerol, 1,3-butyrene glycol or propylene glycol), higher fatty acids (palmitylic acid or linolenic acid), fats and oils (wheat germ) oil, camellia oil, jojoba oil, olive oil, squalene, sunflower oil, macadamia peanut oil, avogard oil, or fatty acid glycerides), etc. may be used, but is not limited thereto. In addition, if necessary, at least one selected from the group consisting of surfactants, moisturizing agents, preservatives, and antioxidants may be added.

The formulation of the cosmetic composition may be in any form applied to hair, for example, solutions, sprays, emulsions, gels, creams, essences, packs, ampoules, lotions, shampoos, soaps, hair products such as oils, etc. It may be one or more selected from the group.

The content of the active ingredient (active compound (sulforaphane, indole-3-carbinol, β-sitosterol, or a combination thereof) and / or extract (solid content)) contained in the cosmetic composition depends on the type of formulation, desired effect, etc. It may be appropriately determined, for example, 0.0001 to 99% by weight, 0.0001 to 90% by weight, 0.0001 to 80% by weight, 0.0001 to 70% by weight, 0.0001 to 60% by weight, 0.0001 to 50% by weight of the total weight of the cosmetic composition, 0.0001 to 40 wt%, 0.0001 to 30 wt%, 0.0001 to 20 wt%, 0.0001 to 10 wt%, 0.01 to 99 wt%, 0.01 to 90 wt%, 0.01 to 80 wt%, 0.01 to 70 wt%, 0.01 to 0.01 wt% 60 wt%, 0.01 to 50 wt%, 0.01 to 40 wt%, 0.01 to 30 wt%, 0.01 to 20 wt%, 0.01 to 10 wt%, 1 to 99 wt%, 1 to 90 wt%, 1 to 80 wt% %, 1 to 70% by weight, 1 to 60% by weight, 1 to 50% by weight, 1 to 40% by weight, 1 to 30% by weight, 1 to 20% by weight, 1 to 10% by weight, 5 to 99% by weight, 5 to 90% by weight, 5 to 80% by weight, 5 to 70% by weight, 5 to 60% by weight, 5 to 50% by weight, 5 to 40% by weight, 5 to 30% by weight, 5 to 20% by weight, 5 to 5% by weight 10 wt%, 10 to 99 wt%, 10 to 90 wt%, 10 to 80 wt%, 10 to 70 wt%, 10 to 60 wt%, 10 to 50 wt%, 10 to 40 wt%, 10 to 30 wt% %, 10 to 20% by weight, 20 to 99% by weight, 20 to 90% by weight, 20 to 80% by weight, 20 to 70% by weight, 20 to 60% by weight, 20 to 50% by weight, 20 to 40% by weight, 20 to 30% by weight, 30 to 99% by weight, within 30 90 wt%, 30 to 80 wt%, 30 to 70 wt%, 30 to 60 wt%, 30 to 50 wt%, 30 to 40 wt%, 40 to 99 wt%, 40 to 90 wt%, 40 to 80 wt% 40 to 70% by weight, 40 to 60% by weight, 40 to 50% by weight, 50 to 99% by weight, 50 to 90% by weight, 50 to 80% by weight, 50 to 70% by weight, 50 to 60% by weight , 60 to 99%, 60 to 90%, 60 to 80%, or 60 to 70%.

The health functional food is a food manufactured using nutrients that are easily deficient in daily meals or raw materials or ingredients having functions useful to the human body (hereinafter referred to as 'functional raw materials'). / or means any food that helps to improve, and there is no particular restriction on the form of the final product. For example, the health functional food may be selected from the group consisting of various foods, beverages, food additives, etc., but is not limited thereto.

The content of the active ingredient (active compound (sulforaphane, indole-3-carbinol, β-sitosterol, or a combination thereof) and / or extract (solid content)) contained in the food composition (health functional food) is the form of the formulation, It may be appropriately determined depending on the desired effect, etc., for example, 0.0001 to 99% by weight, 0.0001 to 90% by weight, 0.0001 to 80% by weight, 0.0001 to 70% by weight, 0.0001 to 60% by weight of the total weight of the pharmaceutical composition, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.01 to 99% by weight, 0.01 to 90% by weight, 0.01 to 80% by weight, 0.01 to 70 wt%, 0.01 to 60 wt%, 0.01 to 50 wt%, 0.01 to 40 wt%, 0.01 to 30 wt%, 0.01 to 20 wt%, 0.01 to 10 wt%, 1 to 99 wt%, 1 to 90 wt% %, 1 to 80% by weight, 1 to 70% by weight, 1 to 60% by weight, 1 to 50% by weight, 1 to 40% by weight, 1 to 30% by weight, 1 to 20% by weight, 1 to 10% by weight, 5 to 99% by weight, 5 to 90% by weight, 5 to 80% by weight, 5 to 70% by weight, 5 to 60% by weight, 5 to 50% by weight, 5 to 40% by weight, 5 to 30% by weight, 5 to 60% by weight 20 wt%, 5 to 10 wt%, 10 to 99 wt%, 10 to 90 wt%, 10 to 80 wt%, 10 to 70 wt%, 10 to 60 wt%, 10 to 50 wt%, 10 to 40 wt% %, 10 to 30% by weight, 10 to 20% by weight, 20 to 99% by weight, 20 to 90% by weight, 20 to 80% by weight, 20 to 70% by weight, 20 to 60% by weight, 20 to 50% by weight, 20 to 40% by weight, 20 to 30% by weight, 30 to 99% by weight %, 30 to 90% by weight, 30 to 80% by weight, 30 to 70% by weight, 30 to 60% by weight, 30 to 50% by weight, 30 to 40% by weight, 40 to 99% by weight, 40 to 90% by weight, 40 to 80% by weight, 40 to 70% by weight, 40 to 60% by weight, 40 to 50% by weight, 50 to 99% by weight, 50 to 90% by weight, 50 to 80% by weight, 50 to 70% by weight, 50 to 60 wt%, 60 to 99 wt%, 60 to 90 wt%, 60 to 80 wt%, or 60 to 70 wt%.

The health functional food includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors or natural flavors, colorants, enhancers (cheese, chocolate, etc.), pectic acid or its salts, alginic acid or its salts, It may further contain at least one selected from the group consisting of organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. The ratio of these additives is generally selected from the range of about 0.00001 to about 20 parts by weight per 100 parts by weight of the total health functional food, but is not limited thereto.

The composition and/or active ingredient (active compound and/or extract) provided herein can be administered in a pharmaceutically effective amount. In the present specification, "pharmaceutically effective amount" or "effective amount" may refer to a dose that contributes to a desired effect (hair growth and/or hair loss inhibition), exhibits an action beneficial to the effect, or achieves the effect. there is. The pharmaceutically effective amount may be prescribed in various ways depending on factors such as formulation method, age, weight, sex, severity of symptoms, administration time, administration interval, administration route, excretion rate, reaction sensitivity, and the like. The effective amount may vary depending on the subject's age, weight, sex, dosage form, health condition, degree of symptoms, etc., and may be divided into once or several times a day at regular intervals according to the judgment of a doctor or pharmacist.

For example, the single or daily dose of the composition is based on the weight of the active ingredient (active compound (sulforaphane, indole-3-carbinol, β-sitosterol, or a combination thereof) and / or extract (solid content)), 0.0001 to 10000 mg/kg, specifically, 0.001 to 1000 mg/kg, 0.001 to 500 mg/kg, 0.001 to 300 mg/kg, 0.001 to 250 mg/kg, 0.01 to 1000 mg/kg, 0.01 to 500 mg/kg kg, 0.01 to 300 mg/kg, 0.01 to 250 mg/kg, 0.1 to 1000 mg/kg, 0.1 to 500 mg/kg, 0.1 to 300 mg/kg, 0.1 to 250 mg/kg, 1 to 1000 mg/kg , 1 to 500 mg/kg, 1 to 300 mg/kg, 1 to 250 mg/kg, 10 to 1000 mg/kg, 10 to 500 mg/kg, 10 to 300 mg/kg, or 10 to 250 mg/kg range, but is not limited thereto. A single or daily dosage may be formulated as one preparation in unit dosage form, formulated in appropriate portions, or introduced into a multi-dose container. The above dosage is an example of an average case, and the dosage may be higher or lower depending on individual differences.

The present specification is broccoli ( Brassica oleracea var. italica) extract, avocado ( Persea americana ) extract, a mixture thereof, or an effective compound derived from the natural extract, which has excellent biosafety and excellent hair growth and / or hair loss inhibitory effect Hair growth It provides a composition for use or hair loss inhibition.

Figure 1a is a graph showing the concentration of testosterone (testosterone) in the plasma of rats to which a broccoli extract, an avocado extract, or a mixture thereof was administered according to an embodiment.
Figure 1b is a graph showing the concentration of dihydrotestosterone (dihydrotestosterone; DHT) in plasma of rats administered with a broccoli extract, an avocado extract, or a mixture thereof according to an embodiment.
2 is a photograph of stained skin tissues of rats administered with a broccoli extract, an avocado extract, or a mixture thereof according to an embodiment.
3 is a graph showing the length of hair follicles in the skin of rats to which a broccoli extract, an avocado extract, or a mixture thereof was administered according to an embodiment.
Figure 4a is a graph showing testosterone concentrations in plasma of rats to which sulforaphane, indole-3-carbinol, and beta-sitosterol were administered individually or in combination.
Figure 4b is a graph showing the concentration of dihydrotestosterone in plasma of rats administered with sulforaphane, indole-3-carbinol, and beta-sitosterol individually or in combination.
5 is a graph showing the length of hair follicles in the skin of rats to which sulforaphane, indole-3-carbinol, and beta-sitosterol were administered individually or in combination.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples. In addition, since those skilled in the art or similar fields of the present application can sufficiently recognize and infer information not described in this specification, the description thereof will be omitted.

Example 1: Preparation of extract

1.1. Preparation of broccoli extract

Broccoli ( Brassica oleracea var. italica) was washed with clean water and then sufficiently dried. To 100 g of powder obtained by crushing dried broccoli, 10 times the volume (500 ml) of water or ethanol (10 to 100% (v/v) ethanol (alcohol)) was added, extracted three times at 70 ° C for more than 3 hours, and then , The filtrate filtered through a 1 μm (micrometer) filter was heated and concentrated until it became 10% (w/w) of the original weight. The obtained concentrate was continuously concentrated, completely dried, and powdered to prepare a broccoli extract powder. Among them, the test was conducted using broccoli water extract powder (hereinafter referred to as BE) using water as an extraction solvent.

1.2. Preparation of Avocado Extract

Avocados ( Persea americana ) were sterilized in chlorinated water for 15 minutes. The avocado pulp was separated and homogenized with a 1% (v/v) citric acid solution. The homogenized solution was lyophilized and powdered and stored frozen for 1 week prior to extraction. 100 g of the prepared freeze-dried powder was dissolved in 500 mL of petroleum ether (CAS No. 101316-46-5) and extracted with a Soxhlet extractor to obtain an oily extract. The extracted oil was pulverized to prepare an avocado extract powder (hereinafter referred to as AE).

Example 2: Testosterone reduction effect of broccoli extract and/or avocado extract

Testosterone and dihydrotestosterone (dihydrotestosterone, hereinafter referred to as DHT) reduction effects of the broccoli extract and/or avocado extract prepared in Example 1 were collected from male Wistar albino rats and tested for testosterone and It was confirmed using the DHT ELISA kit.

Example 2-1. Breeding of laboratory animals

Male Wistar albino rats weighing 180 to 240 g and aged 2 to 3 months were raised under conditions of a constant light-dark cycle with light from 8:00 am to 8:00 pm, a temperature of 22 to 25 ° C, and a relative humidity of 60%. For the feed of the experimental animals, a general pellet-dried feed was used, and feed and water were allowed to be consumed at all times.

Example 2-2. Measurement of testosterone and DHT concentrations after administration of the extract

To the experimental animals reared in Example 2-1, 100 mg of commercially available testosterone (SUSTANON ^® ) was diluted in 100 ml of peanut oil (arachis oil), and 0.2 ml of a testosterone solution was subcutaneously injected every day for a total of 21 days.

In addition, the broccoli extract and / or avocado extract prepared in Example 1 was administered at a dose of 100 mg per 1 kg of body weight of each experimental animal (in the case of the combination group, broccoli extract 67 mg / kg + avocado extract 33 mg / kg ) was administered orally every day for a total of 21 days.

The experimental animal groups treated with the testosterone solution, the broccoli extract, the avocado extract, or the mixture of the broccoli extract and the avocado extract are summarized in Table 1 below.

testosterone
(T; 21 days) Broccoli Extract
(BE 100mg/kg) avocado extract
(AE 100mg/kg) extract mixture
(BE 67mg/kg +AE 33mg/kg) Normal group (Group 1) - - - - Negative control group (Group 2) ○ Experimental group (Group 3) ○ ○ Experimental group (Group 4) ○ ○ Experimental group (Group 5) ○ ○

Testosterone solution and broccoli extract, avocado extract, or broccoli and avocado extract were administered for 21 days, and the next day before skin sampling, the rats' plasma was extracted and tested for testosterone using a testosterone and DHT ELISA kit (Arigo Biolaboratories, Taiwan) according to the manufacturer's instructions. and concentrations of DHT were measured.

The results of measuring the concentrations of testosterone and DHT in plasma of the normal group, the negative control group, and the experimental group are shown in FIGS. 1a and 1b, respectively. As shown in FIGS. 1A and 1B , in the case of the negative control group administered with only the testosterone solution, the concentrations of testosterone and DHT in plasma were significantly increased compared to the normal group. On the other hand, in the case of the experimental groups (Groups 3, 4, and 5) administered with the broccoli extract and/or the avocado extract, the concentrations of testosterone and DHT in plasma decreased. In the case of (Group 5), the concentrations of testosterone and DHT in plasma were greatly reduced to the same extent as those of the normal group (group 1).

Example 3: Confirmation of effect of broccoli extract or avocado extract on hair follicles

Example 3-1. Morphological changes in hair follicles (stained pictures)

By staining the skin tissue of the experimental animal, the change in the shape of the hair follicle was examined. A testosterone solution, broccoli extract, avocado extract, or a mixture thereof was administered to the test animals prepared in Example 2-1 for 21 days, and the next day, the skin of the dorsal region of the test animals was treated with hair removing cream Veet ^® . After hair removal using, incision was made and fixed with 10% (v/v) formalin. After 24 hours, the skin samples were embedded in paraffin wax and sectioned at a uniform thickness of 10 μm, and hair follicles were stained with hematoxylin and eosin. Slides were viewed under a microscope and images were recorded using standard software (Leica, Germany).

Stained photographs of the observed skin tissues of the normal group, the negative control group, and the experimental group are shown in FIG. 2 . As shown in FIG. 2 , in the case of the negative control group administered with only the testosterone solution, many hair follicles in the telogen phase were found. On the other hand, in the case of the experimental groups (Groups 3, 4, and 5) administered with the broccoli extract and/or the avocado extract, the length of the hair follicles increased, and the length of the hair follicles was similar to that of the normal group (Group 1).

Example 3-2. Density measurement of hair follicles

The density of hair follicles in the skin of the normal group, the negative control group, and the experimental group was measured and shown in Table 2 below. The density of the hair follicles was measured by counting the number of hair follicles within a unit area (1 mm 2 ). The obtained results are shown in Table 2.

hair follicle density Increase/decrease rate compared to normal group Normal group (Group 1) 1.31±0.021 - Negative control group (Group 2) 0.91±0.069 -30.53% Experimental group (Group 3) 2.40±0.053* +83.21% Experimental group (Group 4) 2.09±0.032* +59.54% Experimental group (Group 5) 2.61±0.057* +99.24%

(In Table 2, Values are mean ± SEM, n = 15, *p <0.05 as compared to negative control) The rate of change compared to the normal group described in Table 2 was calculated according to Equation 1 below.

(Equation 1)

Increase/decrease rate compared to normal group = (follicle density of negative control group or experimental group - hair follicle density of normal group) / hair follicle density of normal group

As shown in Table 2, in the case of the negative control group administered only with the testosterone solution, the hair follicle density decreased by about 31% compared to the normal group. On the other hand, in the case of the experimental groups (Groups 3, 4, and 5) administered with the broccoli extract and/or the avocado extract, the hair follicle density was about 83% (broccoli extract), about 60% (avocado extract), or about 60%, respectively, compared to the normal group. 99% (a mixture of broccoli extract and avocado extract) showed an excellent effect of increasing.

Example 3-3. Comparison of hair follicle conditions

In the skin of the normal group, the negative control group, and the experimental group, the ratio of the growth phase and the telogen phase of hair follicles was calculated and shown in Table 3 below.

growing up
(anagen) rest period
(telogen) Adolescent/telogen ratio Increase/decrease rate compared to normal group Normal group (Group 1) 66.1 33.9 1.949853 - Negative control group (Group 2) 14.6 85.4 0.17096 -91.23% Experimental group (Group 3) 60.4 39.6 1.525253* -21.78% Experimental group (Group 4) 51.2 48.8 1.04918* -46.19% Experimental group (Group 5) 65.6 34.4 1.906977* -2.20%

*p<0.05 as compared to negative control The rate of change compared to the normal group in Table 3 was calculated according to Equation 2 below.

(Equation 2)

Increase/decrease rate compared to normal group = (growth/resting ratio of negative control or experimental group - growth/resting ratio of normal group) / growth/resting ratio of normal group

As shown in Table 3, in the case of the negative control group administered with only the testosterone solution, the number of follicles in the anagen phase decreased and the number in the telogen phase increased, and the anagen/telogen ratio decreased by about 91% compared to the normal group. On the other hand, in the case of the experimental groups (Groups 3, 4, and 5) administered with the broccoli extract and/or the avocado extract, the growth phase hair follicles increased and the telogen phase hair follicles decreased compared to the negative control group. Among them, especially in the case of the experimental group (Group 5) administered with the mixture of broccoli extract and avocado extract, compared to the negative control group, the hair follicles in the anagen phase increased significantly and the telogen hair follicles decreased significantly, and the anagen/telogen ratio was higher than that of the normal group. appeared to a similar extent.

Example 3-4. Comparison of hair follicle length

The hair follicle length was measured in the skin of the normal group, the negative control group, and the experimental group and is shown in FIG. 3 . The length of the hair follicle was measured using standard software (Leica, Germany) for the length of the dyed hair follicle photographed in Example 3-1, and the results are shown in FIG. 3 .

As shown in FIG. 3, in the case of the negative control group administered with only the testosterone solution, the length of the hair follicle was greatly reduced compared to the normal group. On the other hand, in the case of the experimental groups (Groups 3, 4, and 5) administered with the broccoli extract and/or the avocado extract, the hair follicle length increased compared to the negative control group. Among these, especially in the case of the experimental group (Group 5) administered with a mixture of broccoli extract and avocado extract, the length of the hair follicles increased significantly compared to the negative control group, and showed an excellent effect of increasing the length of the hair follicles than the normal group.

Example 4: Confirmation of the male hormone reducing effect of the compound

To the experimental animals reared in Example 2-1, sulforaphane, indole-3-carbinol, beta-sitosterol or a mixture of the above compounds was orally administered daily at a dose of 10 mg/kg for 21 days.

Experimental animal groups treated with the sulforaphane, indole-3-carbinol, beta-sitosterol or a mixture of the compounds are summarized in Table 4 below.

Testosterone (T; 21 days) Sulforaphane (SFN 10 mg/kg) Indole-3-carbinol (I3C 10mg/kg) Beta-sitosterol (β-sitisterol 10mg/kg) A mixture of compounds (SFN 8 mg/kg + I3C 1 mg/kg + β-sitisterol 1 mg/kg) Normal group (Group A) - - - - - Negative control group (Group B) ○ Experimental group (Group C) ○ ○ Experimental group (Group D) ○ ○ Experimental group (Group E) ○ ○ Experimental group (Group F) ○ ○

Sulforaphane, indole-3-carbinol, beta-sitosterol, or a mixture of the above compounds was administered for 21 days, and the plasma of the rats was extracted the next day, and the concentrations of testosterone and DHT were measured using a testosterone and DHT ELISA kit (Arigo Biolaboratories, Taiwan). was measured (see Example 2-2).

The results of measuring the concentrations of testosterone and DHT in plasma of the control, negative control, and experimental groups are shown in FIGS. 4a (testosterone) and 4b (DHT), respectively. As shown in FIGS. 4a and 4b , in the case of the negative control group administered with only the testosterone solution, the concentrations of testosterone and DHT in plasma were significantly increased compared to the normal group. On the other hand, in the case of the experimental groups (Groups C, D, E, F) administered with sulforaphane, indole-3-carbinol and/or beta-sitosterol, it was found that the concentrations of testosterone and DHT in plasma were significantly decreased. Among these, especially in the case of the experimental group (Group F) administered with a mixture of sulforaphane, indole-3-carbinol and beta-sitosterol, the concentrations of testosterone and DHT in plasma significantly decreased to the same level as that of the normal group (Group A). did

Example 5: Confirmation of the effect of the compound on hair follicles

Example 5-1. Density measurement of hair follicles

Referring to Example 3-2, the density of hair follicles in the skin of the normal group, the negative control group, and the experimental group was measured and shown in Table 5 below.

hair follicle density Change rate compared to normal group (%) Normal group (Group A) 1.31±0.021 - Negative control group (Group B) 0.91±0.069 -30.53% Experimental group (Group C) 1.93±0.102* +47.33% Experimental group (Group D) 1.59±0.74* +21.37% Experimental group (Group E) 2.195±0.093* +67.56% Experimental group (Group F) 2.41±0.064* +83.97%

Values are mean ± SEM, n = 15, *p<0.05 as compared to negative control hair follicle density was expressed as mean value ± mean standard error. The rate of change compared to the normal group was calculated in the same manner as in Equation 1 above.

As shown in Table 5, in the case of the negative control group administered only with the testosterone solution, the hair follicle density was reduced by about 93% compared to the normal group. On the other hand, in the case of the experimental groups (Groups C, D, E, F) administered with sulforaphane, indole-3-carbinol, beta-sitosterol, or a mixture thereof, the hair follicle density was about 47% compared to the normal group (sulforaphane) , about 21% (indole-3-carbinol), about 68% (beta-sitosterol), or about 84% (a mixture of sulforaphane, indole-3-carbinol, and beta-sitosterol) showed excellent effects .

Example 5-2. Comparison of hair follicle conditions

Referring to Example 3-3, the ratio of growth phase and telogen of hair follicles in the skin of the normal group, the negative control group, and the experimental group was calculated and shown in Table 6 below.

growing up
(anagen) rest period
(telogen) Adolescent/telogen ratio Increase/decrease rate compared to normal group Normal group (Group A) 66.1 33.9 1.94 - Negative control group (Group B) 14.6 85.4 0.17 -91.23% Experimental group (Group C) 50.8 49.2 1.03* -47.05% Experimental group (Group D) 46.8 53.2 0.87* -54.88% Experimental group (Group E) 50.2 49.8 1.00* -48.30% Experimental group (Group F) 58.4 41.6 1.40* -28.00%

*p<0.05 as compared to negative control The rate of change compared to the normal group was calculated in the same manner as in Equation 2 above.

As shown in Table 6, in the case of the negative control group administered with only the testosterone solution, the number of hair follicles in the anagen phase decreased and the number in the telogen phase increased, and the anagen/telogen ratio decreased by about 91% compared to the normal group. On the other hand, in the case of the experimental groups (Groups C, D, E, F) administered with sulforaphane, indole-3-carbinol and/or beta-sitosterol, the growth phase hair follicles increased and the telogen phase hair follicles decreased compared to the negative control group. Among them, in particular, in the case of the experimental group (Group 6) administered with a mixture of testosterone, sulforaphane, indole-3-carbinol and beta-sitosterol, compared to the negative control group, hair follicles in the growth phase increased significantly and hair follicles in the telogen phase significantly increased. A decrease was observed.

Example 5-3. Comparison of hair follicle length

Referring to Examples 3-4, hair follicle lengths were measured in the skin of the normal group, the negative control group, and the experimental group and are shown in FIG. 5 . As shown in FIG. 5, in the case of the negative control group administered with only the testosterone solution, the length of the hair follicle was greatly reduced compared to that of the control group. On the other hand, in the case of the experimental groups (Groups C, D, E, F) administered with sulforaphane, indole-3-carbinol and/or beta-sitosterol, the length of hair follicles increased compared to the negative control group. Among these, in the case of the experimental group (Group F) administered with a mixture of sulforaphane, indole-3-carbinol and beta-sitosterol, it was confirmed that the length of the hair follicles significantly increased compared to the negative control group.

Claims (9)

A hair growth composition for oral administration comprising (1) sulforaphane or a salt thereof, and (2) beta-sitosterol or a salt thereof. The hair growth composition for oral administration according to claim 1, further comprising indole-3-carbinol or a salt thereof. The method of claim 2, (1) sulforaphane or a salt thereof, (2) indole-3-carbinol or a salt thereof, and (3) beta-sitosterol (β-sitosterol) or A hair growth composition for oral administration comprising a salt thereof in a weight ratio of 10:0.1 to 5:0.1 to 5. (1) sulforaphane or a salt thereof, and (2) beta-sitosterol (β-sitosterol) or a salt thereof, comprising a pharmaceutical composition for preventing or treating hair loss for oral administration. The pharmaceutical composition for preventing or treating hair loss for oral administration according to claim 4, further comprising indole-3-carbinol or a salt thereof. The method of claim 5, (1) sulforaphane or a salt thereof, (2) indole-3-carbinol or a salt thereof, and (3) beta-sitosterol (β-sitosterol) or A pharmaceutical composition for preventing or treating hair loss for oral administration, comprising a salt thereof in a weight ratio of 10: 0.1 to 5: 0.1 to 5. (1) sulforaphane (sulforaphane) or a salt thereof, and (2) beta-sitosterol (β-sitosterol) or a cosmetic composition for preventing or improving hair loss for oral administration, comprising a salt thereof. The cosmetic composition for preventing or improving hair loss for oral administration according to claim 7, further comprising indole-3-carbinol or a salt thereof. The method of claim 8, wherein (1) sulforaphane or a salt thereof, (2) indole-3-carbinol or a salt thereof, and (3) beta-sitosterol (β-sitosterol) or A cosmetic composition for preventing or improving hair loss for oral administration, comprising a salt thereof in a ratio of 10: 0.1 to 5: 0.1 to 5 by weight.

Images